Attached files
| file | filename |
|---|---|
| EX-99.1 - LETTER FROM JOHN P. WALKER DATED JANUARY 5, 2011 - Paratek Pharmaceuticals, Inc. | dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
January 6, 2011 (January 5, 2011)
Date of Report (date of earliest event reported)
TRANSCEPT PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
| Delaware | 000-51967 | 33-0960223 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
1003 W. Cutting Blvd., Suite #110
Point Richmond, California 94804
(Address of principal executive offices)
(510) 215-3500
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| ITEM 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On January 5, 2011, John P. Walker, a member of the board of directors (the “Board”) of Transcept Pharmaceuticals, Inc. (the “Company”), notified the Company that he will not stand for re-election to the Board at the Company’s 2011 Annual Meeting of Stockholders. Mr. Walker’s decision was not a result of any disagreement with the Company. His term of office as a director of the Company will expire at the Company’s 2011 annual stockholders’ meeting, which is currently scheduled for June 23, 2011.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. |
Description | |
| 99.1 | Letter from John P. Walker dated January 5, 2011 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TRANSCEPT PHARMACEUTICALS, INC.
| ||||
| Date: January 6, 2011 | ||||
| By: | /S/ MARILYN E. WORTZMAN | |||
| Name: | Marilyn E. Wortzman | |||
| Title: | Vice President, Finance | |||
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | Letter from John P. Walker dated January 5, 2011 | |